艺妙神州启动科创板IPO：董事长何霆毕业于清华、控股22%

Group 1 - Beijing Yimiao Shenzhou Biopharmaceutical Co., Ltd. (referred to as "Yimiao Shenzhou") completed its IPO counseling record with the Beijing Securities Regulatory Bureau, aiming for an IPO on the Sci-Tech Innovation Board, with CITIC Securities as the counseling institution [1] - The company was established on April 14, 2015, with a registered capital of 30 million RMB, focusing on gene cell drugs for the treatment of malignant tumors [1] - The controlling shareholder is He Ting, who directly and indirectly controls 21.92% of the company's shares, and he graduated from Tsinghua University with a background in cancer biology [1] Group 2 - The company has undertaken over ten national and provincial scientific research projects, collaborating with top hospitals such as Beijing Cancer Hospital, Tsinghua Changgung Hospital, Peking Union Medical College Hospital, and others for CAR-T drug clinical research [2] - Yimiao Shenzhou has been recognized as a national high-tech enterprise, a postdoctoral research workstation, a Beijing engineering research center, a specialized and innovative enterprise in Beijing, and a CAR-T joint research and development center [2]